Diversité de genre, consommation de substances, santé mentale.
Cure, vaccination, réservoirs…
COVID-19, variole simienne, ITSS…
1 juillet 2023
The hepatitis D virus (HDV) or delta hepatitis is the most difficult form of viral hepatitis to treat. It is also the most aggressive, with the most rapid evolution to cirrhosis, hepatocellular carcinoma, and death. HDV is found globally with areas of greater prevalence, known as hotspots. Due to the dependence of HDV on the hepatitis B virus (HBV), it is likely that as HBV vaccination rates increase the population vulnerable to HDV will decrease. There is currently no HDV vaccine, leaving those infected with HBV vulnerable to HDV. HDV utilizes the host for almost all its replicative cycle, leading to a paucity of true antiviral targets. Diagnosis depends on accurate testing for HDV, and as testing has improved and expanded, the full extent of HDV has increasingly been appreciated. Although not satisfactory, the mainstay of therapy thus far has been interferon alpha and liver transplant where indicated. However, as the molecular virology of HDV has been unlocked, there has been a corresponding development of multiple therapeutic options. It is these therapeutic options that hold the promise of cure. Unmet needs include identifying patients infected with HDV, accurate noninvasive staging of their liver disease, and easy to administer curative therapies. It is hoped that the next decade will bring us substantively closer to meeting all unmet needs and closer towards the eradication of HDV.
Auteur(s) : Heller, T., & al.
© PNMVH 2024
Programme national de mentorat sur le VIH et les hépatites